Per has more than 25 years’ experience in the biotech and pharmaceutical industry within product development and business development. He has founded and run several biotech companies, worked as a biotech consultant and been an entrepreneur in residence with Novo Holdings. His primary therapeutic areas of interest have been immunology, vaccines, haemostasis and oncology. Per holds a D.Phil. from the University of Oxford and has 6 years of laboratory experience within immunology and infectious diseases prior to starting his industrial career.

Hans Henrik brings more than two decades of financial leadership in the life science sector. He has served as CFO in both private and public companies, successfully leading financing strategies and M&A transactions, and supporting organizational growth and operational scale-up.

Jamila joins from GSK, where she held a senior leadership role in Vaccine Research and Development. She brings over 20 years of experience advancing vaccines from discovery through late-stage development and regulatory approval, with a strong track record in global program execution.

Lidia has more than 25 years’ R&D experience in the industry, with focus on clinical development, both in pharmaceutical companies and in biotech. She spent more than 20 years of her industry career in development of prophylactic vaccines and has led several large phase 3 clinical programs. She holds a Medical Degree from the University of Ghent (Belgium) and is specialized in Pharmaceutical Medicine.

Bengt holds a PhD in Immunotechnology from Lund University. He has 20 years of experience heading research groups at Lund University and Denmark Technical University (DTU) within the research areas of immunology, vaccinology, and infectious disease. He has been the main supervisor for several completed PhD and postdoctoral projects. In parallel to his current assignment as the CSO of MinervaX, Bengt is an Associate Professor at the Faculty of Medicine, Lund University.

Ms. Genthe has +25 years’ experience in Regulatory Affairs, including leading FDA inspections and major filings, including the submission for palivizumab (Synagis®), the first monoclonal antibody developed into a vaccine. Ms. Genthe received a M.Sc in Biotechnology from Johns Hopkins University in Maryland. Ms. Genthe joined MinervaX in 2024, and currently serves as Senior Vice President of Quality and Regulatory. Prior to MinervaX, Ms. Genthe was Vice President of Regulatory Affairs at GeoVax. Prior to GeoVax, Ms. Genthe served in several senior regulatory leadership positions at Pfizer, Teva, and Genpact.

Julie has over 15 years of biotechnology and pharmaceutical leadership, blending scientific depth with operational execution. She has a proven track record of advancing complex biologics from R&D through late-stage development, with CMC expertise across the product lifecycle. Julie holds an industrial Ph.D. in Biotechnology and an M.Sc. in Nanoscience from the University of Copenhagen.